Customize
Quick Links
Specialties

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. These activites are not approved for AMA PRA Category 1 Credit

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie, AstraZeneca, BeyondSpring Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation, Genentech, Ignyta, Lilly, Merck Sharp & Dohme Corp, Novartis Pharmaceuticals Corporation, and Takeda Oncology.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Community Practice Connections™: 18th Annual International Lung Cancer Congress® PER Pulse™ Recap

PER Pulse Recap

PER Pulse™ Recap


Overview and Updates in Advanced Melanoma and Immunotherapy

1 of 3
PER Pulse™ Recap

Moving Lung Cancer Immunotherapy into Earlier Stages

The 18th Annual International Lung Cancer Congress®, held July 27-29, 2017, was planned to convey state-of-the-art multidisciplinary approaches for the care of patients with lung cancer, as well as to provide physicians with an update on new approaches and agents that will change the management of patients with lung cancer. This first of 3 PER Pulse™ Recaps from the International Lung Cancer Congress® focuses on developments in immunotherapy in earlier stages of lung cancer.

Initially approved for patients with metastatic, platinum-pretreated, non–small cell lung cancer (NSCLC), immunotherapy has become established in the first-line setting and has also demonstrated clinical benefit in stage III NSCLC. In October 2016, single-agent pembrolizumab was approved as first-line therapy in patients with advanced NSCLC and a PD-L1 expression level of ≥50% based on the phase III KEYNOTE-024 trial, which compared single-agent pembrolizumab to standard platinum-based chemotherapy. In May 2017, the combination of pembrolizumab and carboplatin/pemetrexed received accelerated approval for first-line therapy of patients with nonsquamous NSCLC regardless of PD-L1 expression levels. More recently, the phase III PACIFIC trial randomized patients with unresectable stage III NSCLC who did not experience disease progression following concurrent chemoradiation therapy to receive either durvalumab or placebo. The co-primary endpoint of progression-free survival was superior in the durvalumab arm (16.8 vs 5.6 months; HR, 0.52; P <.001), and the study continues to mature for the endpoint of overall survival.

For additional commentary about these topics and others, visit www.gotoper.com to access more resources from the 18th Annual International Lung Cancer Congress.®

2 of 3
PER Pulse™ Recap

Changing Standards of Care for ALK-Rearranged NSCLC

The 18th Annual International Lung Cancer Congress®, held July 27-29, 2017, was planned to convey state-of-the-art multidisciplinary approaches for the care of patients with lung cancer, as well as to provide physicians with an update on new approaches and agents that will change the management of patients with lung cancer. This second of 3 PER Pulse™ Recaps from the International Lung Cancer Congress® focuses on recent data and approvals for patients with non–small cell lung cancer (NSCLC) and rearrangements in the anaplastic lymphoma kinase (ALK) gene.

Crizotinib has been the first-line standard of care for patients with ALK-rearranged NSCLC; however, other agents have demonstrated activity in this setting. Recently, the phase III ASCEND-4 trial compared ceritinib with platinum-based chemotherapy, meeting the primary endpoint of progression-free survival (PFS) and leading to approval in May 2017. The phase III global ALEX trial compared alectinib to crizotinib, with alectinib demonstrating superiority in the primary endpoint of PFS. The 12-month PFS was 68% with alectinib, compared with 49% with crizotinib (HR, 0.47; P <.001). Alectinib is under priority review, with a decision expected in November 2017. Finally, for patients whose disease progresses during crizotinib therapy or who become intolerant of crizotinib, the next-generation ALK inhibitor brigatinib was granted accelerated approval in April 2017.

For additional commentary about these topics and others, visit www.gotoper.com to access more resources from the 18th Annual International Lung Cancer Congress.®

3 of 3
PER Pulse™ Recap

Advances in EGFR and BRAF Inhibition in Lung Cancer

The 18th Annual International Lung Cancer Congress®, held July 27-29, 2017, was planned to convey state-of-the-art multidisciplinary approaches for the care of patients with lung cancer, as well as to provide physicians with an update on new approaches and agents that will change the management of patients with lung cancer. This third of 3 PER Pulse™ Recaps from the International Lung Cancer Congress® focuses on new approaches for patients with non–small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR) or BRAF gene.

First-line standards of care for patients with EGFR mutation-positive NSCLC include erlotinib, afatinib, and gefitinib; however, next-generation EGFR inhibitors are being developed in this setting. The phase III FLAURA trial randomized patients with EGFR mutation-positive NSCLC to first-line therapy with osimertinib or standard approaches (erlotinib or gefitinib). Progression-free survival (PFS) was superior in the osimertinib arm (18.9 vs 10.2 months; HR, 0.46; P .0001), and osimertinib was granted breakthrough therapy designation in October 2017. Earlier in 2017, results of the phase III ARCHER 1050 study were presented, in which dacomitinib demonstrated superior PFS compared with gefitinib (14.7 vs 9.2 months, HR, 0.59; P <.0001).

Inhibition of BRAF/MEK is a proven therapeutic approach in patients with melanoma. In June 2017, the combination of dabrafenib and trametinib was approved for patients with BRAF V600E-positive NSCLC. This approval was based on a phase II trial examining the combination of dabrafenib plus trametinib, with separate cohorts for newly diagnosed patients and for patients with platinum-pretreated NSCLC. The primary endpoint of overall response rate was similar (63%-64%) in both cohorts.

For additional commentary about these topics and others, visit www.gotoper.com to access more resources from the 18th Annual International Lung Cancer Congress.®







Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
31
Filter By